{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:04Z","timestamp":1793414104801,"version":"4.5.0"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.8501","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T15:01:59Z","timestamp":1593615719000},"page":"e208501","source":"Crossref","is-referenced-by-count":131,"title":["Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes"],"prefix":"10.1001","volume":"3","author":[{"given":"Shannon","family":"Gallagher","sequence":"first","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisha","family":"Hughes","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Wagner","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Placede","family":"Tshiaba","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rosenthal","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin B.","family":"Roa","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison W.","family":"Kurian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Stanford University, Palo Alto, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Domchek","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Garber","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Lancaster","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"},{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey N.","family":"Weitzel","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gutin","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry S.","family":"Lanchbury","sequence":"additional","affiliation":[{"name":"Myriad Genetics Inc, Salt Lake City, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Robson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"issue":"3","key":"zoi200360r1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.molonc.2010.04.011","article-title":"Genetic susceptibility to breast cancer.","volume":"4","author":"Mavaddat","year":"2010","journal-title":"Mol Oncol"},{"issue":"10","key":"zoi200360r2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1054\/bjoc.2000.1407","article-title":"Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases.","volume":"83","author":"Anglian Breast Cancer Study Group","year":"2000","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi200360r3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10911-011-9213-5","article-title":"Inherited mutations in breast cancer genes\u2014risk and response.","volume":"16","author":"Shuen","year":"2011","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"23","key":"zoi200360r4","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","article-title":"Gene-panel sequencing and the prediction of breast-cancer risk.","volume":"372","author":"Easton","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi200360r5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1086\/341943","article-title":"A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.","volume":"71","author":"Vahteristo","year":"2002","journal-title":"Am J Hum Genet"},{"issue":"8","key":"zoi200360r6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/ng1837","article-title":"ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.","volume":"38","author":"Renwick","year":"2006","journal-title":"Nat Genet"},{"issue":"2","key":"zoi200360r7","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/ng1959","article-title":"PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.","volume":"39","author":"Rahman","year":"2007","journal-title":"Nat Genet"},{"issue":"9","key":"zoi200360r8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cancergen.2016.08.005","article-title":"Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.","volume":"209","author":"Leedom","year":"2016","journal-title":"Cancer Genet"},{"issue":"1","key":"zoi200360r9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00066","article-title":"Breast and ovarian cancer penetrance estimates derived from germline multiple-gene sequencing results in women.","author":"Kurian","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"zoi200360r10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1158\/1055-9965.EPI-17-1144","article-title":"Common genetic variation and breast cancer risk\u2014past, present, and future.","volume":"27","author":"Lilyquist","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"zoi200360r11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ng.3242","article-title":"Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.","volume":"47","author":"Michailidou","year":"2015","journal-title":"Nat Genet"},{"issue":"5","key":"zoi200360r12","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv036","article-title":"Prediction of breast cancer risk based on profiling with common genetic variants.","volume":"107","author":"Mavaddat","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"zoi200360r13","article-title":"Development and validation of a clinical polygenic risk score to predict breast cancer risk.","author":"Hughes","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"zoi200360r14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes.","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"issue":"8","key":"zoi200360r15","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.32541","article-title":"A case\u2013control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density.","volume":"146","author":"Brentnall","year":"2020","journal-title":"Int J Cancer"},{"issue":"7","key":"zoi200360r16","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1200\/JCO.2016.69.8944","article-title":"impact of a panel of 88 single nucleotide polymorphisms on the risk of breast cancer in high-risk women: results from two randomized tamoxifen prevention trials.","volume":"35","author":"Cuzick","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi200360r17","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1038\/s41436-018-0406-9","article-title":"BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors.","volume":"21","author":"Lee","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"zoi200360r18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1001\/jamaoncol.2017.4881","article-title":"Use of single-nucleotide polymorphisms and mammographic density plus classic risk factors for breast cancer risk prediction.","volume":"4","author":"van Veen","year":"2018","journal-title":"JAMA Oncol"},{"issue":"36","key":"zoi200360r20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.14694\/EDBK_158817","article-title":"Refining breast cancer risk stratification: additional genes, additional information.","volume":"35","author":"Kurian","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"zoi200360r21","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrclinonc.2016.90","article-title":"Counselling framework for moderate-penetrance cancer-susceptibility mutations.","volume":"13","author":"Tung","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"zoi200360r22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/jmedgenet-2017-105188","article-title":"Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group.","volume":"55","author":"Taylor","year":"2018","journal-title":"J Med Genet"},{"issue":"23","key":"zoi200360r23","doi-asserted-by":"publisher","first-page":"9742","DOI":"10.1158\/0008-5472.CAN-10-1907","article-title":"Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.","volume":"70","author":"Antoniou","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"zoi200360r24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ajhg.2008.02.008","article-title":"Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.","volume":"82","author":"Antoniou","year":"2008","journal-title":"Am J Hum Genet"},{"issue":"3","key":"zoi200360r25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003212","article-title":"Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.","volume":"9","author":"Couch","year":"2013","journal-title":"PLoS Genet"},{"issue":"3","key":"zoi200360r26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003173","article-title":"Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk.","volume":"9","author":"Gaudet","year":"2013","journal-title":"PLoS Genet"},{"issue":"11","key":"zoi200360r27","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"zoi200360r28","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"zoi200360r29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12885-015-1224-y","article-title":"Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk.","volume":"15","author":"Judkins","year":"2015","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi200360r30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s10549-014-3065-9","article-title":"Development and validation of a new algorithm for the reclassification of genetic variants identified in the BRCA1 and BRCA2 genes.","volume":"147","author":"Pruss","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"zoi200360r31","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/gim.2016.31","article-title":"Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model.","volume":"18","author":"Lee","year":"2016","journal-title":"Genet Med"},{"issue":"5","key":"zoi200360r34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/gim.2016.147","article-title":"Genetic modifiers of CHEK2*1100delC-associated breast cancer risk.","volume":"19","author":"Muranen","year":"2017","journal-title":"Genet Med"},{"issue":"4","key":"zoi200360r35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","article-title":"CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.","volume":"26","author":"Weischer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"23","key":"zoi200360r36","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1200\/JCO.2016.66.5844","article-title":"Age- and tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC carriers.","volume":"34","author":"Schmidt","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi200360r37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/bcr3591","article-title":"Common breast cancer risk variants in the post-COGS era: a comprehensive review.","volume":"15","author":"Maxwell","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"1","key":"zoi200360r38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA).","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"zoi200360r39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1158\/1055-9965.EPI-15-0838","article-title":"Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian Breast Cancer Family Registry.","volume":"25","author":"Dite","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"12","key":"zoi200360r40","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1038\/ng.3785","article-title":"Identification of ten variants associated with risk of estrogen-receptor\u2013negative breast cancer.","volume":"49","author":"Milne","year":"2017","journal-title":"Nat Genet"},{"issue":"2","key":"zoi200360r41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"},{"issue":"7678","key":"zoi200360r43","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature24284","article-title":"Association analysis identifies 65 new breast cancer risk loci.","volume":"551","author":"Michailidou","year":"2017","journal-title":"Nature"},{"key":"zoi200360r19","volume-title":"NCCN Clinical Practice Guidelines in Oncology, Genetic\/Familial High-risk Assessment: Breast and Ovarian","author":"Daly","year":"2019"},{"key":"zoi200360r33","volume-title":"SEER Cancer Statistics Review, 1975-2015","author":"Noone","year":"2017"},{"key":"zoi200360r42","volume-title":"Modern Epidemiology","author":"Rothman","year":"2008"},{"key":"zoi200360r32","unstructured":"National Cancer Institute. Cancer stat facts; female breast cancer: 2014. Surveillance, Epidemiology, and End Results Program. Accessed May 27, 2020. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html?"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2767768\/gallagher_2020_oi_200360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:33:15Z","timestamp":1723163595000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2767768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.8501","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}